Clinical Trial Update: Safety of Chlamydia Vaccine CTH522 in Healthy Women Aged 18 to 45 Years [Phase 1]

View source ↗

Summary

Phase 1 study evaluating the safety of the CTH522 vaccine targeting Chlamydia trachomatis in healthy women aged 18 to 45; the trial has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chlamydia Trachomatis Infection

Drugs mentioned

• CTH522 vaccine (CTH522)

Snippet

Sponsor: Statens Serum Institut | Conditions: Chlamydia Trachomatis | Phase 1 | Status: COMPLETED